Test & Treat

Access to effective oral treatments for COVID-19, especially for high-risk populations and those without access to vaccination, can help save lives and limit the impact of future surges. But these therapies require access to accurate, rapid tests to be most valuable, and challenges remain on supply, demand, and financing for both tests and oral therapies. In our recent report, Pills to People, we lay out key recommendations to enable more equitable global access to oral therapies and support implementation of test-and-treat strategies.

More to Explore

The COVID GAP team is tracking key metrics on both testing and equitable access to oral therapeutics. Explore the pages below for data and further insights on each of these areas.

Testing

Test-and-treat strategies will be essential for the roll out of oral therapeutics to treat COVID-19.

Supply & Demand of Oral Therapeutics

The supply of oral therapeutics for the treatment of COVID-19 is expected to be limited in 2022.

Licensing for Oral Therapeutics

Both Merck and Pfizer have taken steps to increase supply and access to their drugs through licensing.

Pills to People: Accelerating Equitable Global Access to Oral Therapeutics for COVID-19